• Explore /
  • Poster
  • / A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).

A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).

Abstract Poster

Authors

null

Julia Katharina Schwarze

Department of Medical Oncology, Vrije Universiteit Brussel (VUB)/ Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Julia Katharina Schwarze , Wietse Geens , Jens Tijtgat , Gil Awada , Laura Seynaeve , Anne-Marie Vanbinst , Hendrik Everaert , Alex Michotte , Michaël Bruneau , Ivan Van Riet , Sandra Tuyaerts , Johnny Duerinck , Bart Neyns

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Primary CNS Tumors–Glioma

Clinical Trial Registration Number

NCT03233152

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2033)

DOI

10.1200/JCO.2022.40.16_suppl.2033

Abstract #

2033

Poster Bd #

371

Abstract Disclosures

Similar Posters

First Author: Julia Katharina Schwarze

First Author: John H. Sampson

First Author: John Howard Sampson

First Author: Paul James Mulholland